

Biota Holdings Limited

ACN 006 479 081

10/585 Blackburn Road

Notting Hill VIC 3168

Australia

T +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au

For Immediate Release

Melbourne, Australia — 11 February 2009

GSK imports additional Relenza to Japan

Biota Holdings Limited (ASX:BTA) today announced that GlaxoSmithKline (GSK) has advised of the current Relenza supply situation in respect to the key market of Japan.

Biota earns a 7% royalty on all global sales of Relenza by GSK.

A copy of the GSK release is attached.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza™.

Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to AstraZeneca and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals. Inverness Medical markets Biota's co-developed OIA FLU influenza diagnostics.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.

BioStar® OIA® FLU and BioStar® OIA® FLU A/B are registered trademarks of Inverness Medical.

*Further information available at www.biota.com.au

Investor / Analyst Enquiries**Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

Media Enquiries

Jo Lynch

Hinton & Associates

T: +61 3 9600 1979

M: +61 411 208 101

To the media

10th February 2009

GlaxoSmithKline K.K.

Additional Supply of anti-influenza virus drug *Relenza* for this flu season

GlaxoSmithKline K.K. (Head Office: Shibuya-ku, Tokyo, President: Marc Dunoyer, hereinafter referred to as GSK) has decided, based on this season's epidemic situation, to additionally import its anti-influenza virus drug *Relenza* (generic name: zanamivir hydrate) in order to maintain a stable supply.

2 million packs of *Relenza* are to be additionally imported. 0.4 million packs will be available in February, 0.6 million packs in March and 1 million packs in April.

GSK originally prepared for this flu season with 3 million packs of *Relenza*. This quantity is equivalent to meeting the requirement for half the prescriptions of anti-influenza virus drugs in an average year. However, due to reports that most of the prevailing A/H1N1 influenza virus, which accounts for about half of the current epidemic, are resistant to another anti-influenza virus drug this year, attention and demand for *Relenza* has increased dramatically.

GSK believes that currently, there is enough *Relenza* in distribution in the market, but in order to prevent stock accumulation, GSK is controlling its shipment.

The additional importation of *Relenza* will enable GSK to maintain a stable supply. Although it is not possible to predict the size and duration of this season's flu epidemic, GSK will continue with our efforts to provide *Relenza* to all the patients who need it and promote its appropriate use.

□□□□□□□□□□ **Do more, feel better, live longer**

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and health care companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

<Enquiries from the media>

Naomi Yoshida or Yoshiaki Komatsu

Tel: 03-5786-5041/5030

<http://glaxosmithkline.co.jp>